echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Courier! Eli Lilly PD-1 agonist is clinically declared in China

    Courier! Eli Lilly PD-1 agonist is clinically declared in China

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 23, the official website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration of China announced that Eli Lilly and Company had applied for clinical trials


    A monoclonal antibody that binds to and excites the PD-1 receptor, with the potential to become a "first-in-class" therapy, has completed a Phase 2 clinical trial overseas for the treatment of rheumatoid arthritis

    Screenshot source: CDE official website

    The PD-1 target has played an extremely important role


    The PD-1 target has played an extremely important role


    Screenshot Source: References[3]

    Peresolimab Injection (LY3462817), developed by Eli Lilly, is a PD-1 agonist that is being studied for the treatment of rheumatoid arthritis and other autoimmune diseases


    Research is underway to treat rheumatoid arthritis and other autoimmune diseases that bind to human PD-1 and act as its agonist, inhibiting the activation and expansion of lymphocytes


    A Phase 2 study evaluating the efficacy and safety of LY3462817 in patients with moderate to severely active rheumatoid arthritis has been completed

    In the global context, drug development for PD-1 for autoimmune diseases is not active


    It is expected that Eli Lilly's PD-1 receptor agonist will progress smoothly in clinical research and make an early breakthrough to bring new treatment options


    Resources:

    Resources:

    [1] China State Food and Drug Administration Drug Evaluation Center (CDE) official website.


    [1] China State Food and Drug Administration Drug Evaluation Center (CDE) official website.


    Zheng Zhongqing,Jiao Guohui,Guo Liping.


    [3] Eli Lilly R&D Activity Day 2021 PPT
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.